23

The Worldwide Asthma Drugs Industry is Expected to Reach $34 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022
General Health, Pharmaceutical, Health, CAGR, United States Environmental Protection Agency, Population, Route of administration, Review, Public health, Allergy, Infection, Mortality, Administration, EPA, COVID-19, 23, 2009 Davis Cup, Inflammation, Particulates, Environment, World, WHO, Medication, Nitrogen dioxide, Gene, Air pollution, Distribution (marketing), Asthma, Carbon monoxide, Research, Distribution, Child, European Respiratory Society, Respiratory system, Drug discovery, Immune system, NO2, Degenerative disease, Health, Quality of life, Illinois Environmental Protection Agency, Stanford University, Bacteria, World Health Organization, SHS, Chronic obstructive pulmonary disease, Patient, Bronchial hyperresponsiveness, Center, Risk, Mark (given name), Prevalence, Organization, Pharmaceutical industry, Fossil fuel

The asthma drugs market is projected to reach US$ 34,136.10 million in 2028 from US$ 24,239.17 million in 2021; it is estimated to grow at a CAGR of 5.0 % during 2021-2028.

Key Points: 
  • The asthma drugs market is projected to reach US$ 34,136.10 million in 2028 from US$ 24,239.17 million in 2021; it is estimated to grow at a CAGR of 5.0 % during 2021-2028.
  • According to a review paper titled "Impact of Air Pollution on Asthma Outcomes" by Tiotiu et.al., air pollution hampered asthma outcomes in adults and children.
  • Through these research works, the drug discovery and development for asthma is being expedited, which is driving the asthma drug market.
  • Various recommendations were also released, such as stocking up on asthma drugs to prevent the shortage of drugs for asthmatic patients.

Global Wearable Sensor Market Forecast to 2028 - COVID-19 Impact and Analysis

Retrieved on: 
Tuesday, May 24, 2022
AR, CES, Computer, Nausea, Food, US Food Sovereignty Alliance, Blood pressure, CVD, Electronics, IOT, Woman, IDC, American Heart Association, Consumer Electronics Show, Samsung, VR, Photoplethysmogram, COVID-19, Hangover, Artificial intelligence, Cardiac output, Police, Semiconductor, International Data Group, Research report, Industry, Awareness, Motorola Moto, Government, Time, Anxiety, Vomiting, Mobvoi, Degenerative disease, Respiration, Nanotechnology, Adoption, Tablet, CAGR, Oxygen, LLC, Miniaturization, 23, Growth, Abbott Laboratories, Vertical, Motion sickness, PPG, Mobile phone, Medical imaging, Medical device, Consumer electronics, Realme, Apple

DUBLIN, May 24, 2022 /PRNewswire/ --The "Wearable Sensor Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Sensor Type, Application and Vertical" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 24, 2022 /PRNewswire/ --The "Wearable Sensor Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Sensor Type, Application and Vertical" report has been added to ResearchAndMarkets.com's offering.
  • According to the latest research report, titled 'Wearable Sensor Market Forecast to 2028 - COVID-19 Impact and Global Analysis,' the market is expected to grow from US$ 1,906.74 million in 2021 to reach US$ 5,762.57 million by 2028.
  • With the growing consumer awareness, the adoption of smart wearable devices is on the rise in the healthcare sector.
  • Thus, the increasing demand for wearables devices in healthcare applications drives the global wearable sensors market.

Insights on the Wearable Sensor Global Market to 2028 - Burgeoning Popularity of Connected Devices Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022
Technology, Hardware, Consumer Electronics, AR, CES, Computer, Nausea, Food, US Foods, Blood pressure, CVD, Electronics, IOT, Woman, IDC, American Heart Association, Consumer Electronics Show, Samsung, VR, Photoplethysmogram, COVID-19, Hangover, Artificial intelligence, Cardiac output, Police, Semiconductor, International Data Group, Industry, Awareness, Motorola Moto, Government, Time, Anxiety, Vomiting, Mobvoi, Degenerative disease, Respiration, Nanotechnology, Adoption, Tablet, CAGR, Oxygen, LLC, Miniaturization, 23, Growth, Abbott Laboratories, Vertical, Motion sickness, PPG, Mobile phone, Medical imaging, Medical device, Consumer electronics, Realme, Apple

The "Wearable Sensor Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Sensor Type, Application and Vertical" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Wearable Sensor Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Sensor Type, Application and Vertical" report has been added to ResearchAndMarkets.com's offering.
  • With the growing consumer awareness, the adoption of smart wearable devices is on the rise in the healthcare sector.
  • Fit bits, smartwatches, and pulse oximeters are among the wearable systems incorporated with optical sensors to provide real-time patient health tracking solutions.
  • Thus, the increasing demand for wearables devices in healthcare applications drives the global wearable sensors market.

4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting

Retrieved on: 
Sunday, October 10, 2021
Private Securities Litigation Reform Act, Patient, Severe cognitive impairment, ID, Risk, Therapy, Choroideremia, Molecule, Fabry disease, COVID-19, Retina, AMD, US, Douglas Jabs, Tissue, GLOBE, Safety, Webcast, Doctor of Philosophy, Cardiology, Society, U.S. Securities and Exchange Commission, ASRS, University, SUN, RPGR, National Eye Institute, Security (finance), Senior, EDT, R100, Clinical trial, University of Michigan, 23, Shetty, Annual general meeting, Medical imaging, Pharmaceutical industry, Vaccine

The interim data were presented today in a late-breaking presentation at the American Society of Retina Specialists (ASRS) 39th Annual Meeting.

Key Points: 
  • The interim data were presented today in a late-breaking presentation at the American Society of Retina Specialists (ASRS) 39th Annual Meeting.
  • We plan to explore development paths that include treating both early stage and advanced patient populations.
  • 4D-125 was well-tolerated in all eight XLRP patients, including in five patients at the top dose level of 1E12 vg/eye.
  • 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients.